Literature DB >> 11115952

Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy.

A Tuldrà1, C R Fumaz, M J Ferrer, R Bayés, A Arnó, M Balagué, A Bonjoch, A Jou, E Negredo, R Paredes, L Ruiz, J Romeu, G Sirera, C Tural, D Burger, B Clotet.   

Abstract

BACKGROUND: Nearly perfect compliance seems to be indispensable to obtain the maximum benefit from highly active antiretroviral therapy (HAART). Interventions to ensure a high level of adherence during a relatively long-term period of therapy are necessary.
METHODS: This is a prospective, randomized, two-arm controlled study including patients starting their first-or second-line HAART who were randomized to receive psychoeducative intervention to implement adherence (experimental group [EG]) or a usual medical follow-up (control group [CG]). We aimed to study the efficacy of a psychoeducative intervention to ensure long-term adherence to HAART, its relation with the virologic efficacy of treatment, and to determine the variables related to long-term adherence. Visits were made at weeks 0, 4, 24, and 48 for data collection. Self-reported adherence was registered at each visit and its veracity was tested by randomized blood analyses performed without previous warning to 40% of patients. Appropriate adherence was defined as the consumption of >/=95% of medication prescribed. Statistical analyses were performed both by the as treated (AT) and the intention to treat missing = failure (ITT) methods.
RESULTS: In all, 116 patients were included. At week 48, 94% of patients in the EG versus 69% controls achieved adherence >/=95% (p =.008); 89% of patients in the EG versus 66% controls had HIV-1 RNA levels <400 copies/ml (p =.026). Overall, 85% of patients with adherence >/=95% but only 45% of those with adherence <95% had viral load (VL) <400 copies/ml (p =. 008). In multivariate analysis, variables significantly related to adherence were having received a psychoeducative intervention (odds ratio [OR], 6.58; p =.04), poor effort to take medication (OR, 5.38; p =.03), and high self-perceived capacity to follow the regimen (OR, 13.76; p =.04). Self-reported adherence and drug plasma levels coincided in 93% of cases. However, differences in adherence did not reach statistical significance in the ITT analysis although a clear tendency toward benefit was observed in EG.
CONCLUSIONS: Specific and maintained psychoeducative interventions based on excellence on clinical practice are useful to keep high levels of adherence as well as high levels of viral suppression. There is a clear relation between high adherence levels and virologic success. Assessment of certain specific variables related to adherence may be helpful to monitor patient's compliance in the clinical setting.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11115952     DOI: 10.1097/00126334-200011010-00003

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  31 in total

Review 1.  Measuring adherence to highly active antiretroviral therapy: implications for research and practice.

Authors:  Thomas Kerr; John Walsh; Elisa Lloyd-Smith; Evan Wood
Journal:  Curr HIV/AIDS Rep       Date:  2005-11       Impact factor: 5.071

2.  A 2-arm, randomized, controlled trial of a motivational interviewing-based intervention to improve adherence to antiretroviral therapy (ART) among patients failing or initiating ART.

Authors:  Carol E Golin; Joanne Earp; Hsiao-Chuan Tien; Paul Stewart; Carol Porter; Lynn Howie
Journal:  J Acquir Immune Defic Syndr       Date:  2006-05       Impact factor: 3.731

3.  Modified directly observed therapy for antiretroviral therapy: a primer from the field.

Authors:  Kathy Goggin; Robin J Liston; Jennifer Adelson Mitty
Journal:  Public Health Rep       Date:  2007 Jul-Aug       Impact factor: 2.792

4.  Maximizing the impact of HIV prevention efforts: interventions for couples.

Authors:  Amy Medley; Rachel Baggaley; Pamela Bachanas; Myron Cohen; Nathan Shaffer; Ying-Ru Lo
Journal:  AIDS Care       Date:  2013-05-08

Review 5.  Interventions for Enhancing Adherence to Antiretroviral Therapy (ART): A Systematic Review of High Quality Studies.

Authors:  Lawrence Mbuagbaw; Bhairavi Sivaramalingam; Tamara Navarro; Nicholas Hobson; Arun Keepanasseril; Nancy J Wilczynski; R Brian Haynes
Journal:  AIDS Patient Care STDS       Date:  2015-03-31       Impact factor: 5.078

6.  Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel.

Authors:  Melanie A Thompson; Michael J Mugavero; K Rivet Amico; Victoria A Cargill; Larry W Chang; Robert Gross; Catherine Orrell; Frederick L Altice; David R Bangsberg; John G Bartlett; Curt G Beckwith; Nadia Dowshen; Christopher M Gordon; Tim Horn; Princy Kumar; James D Scott; Michael J Stirratt; Robert H Remien; Jane M Simoni; Jean B Nachega
Journal:  Ann Intern Med       Date:  2012-03-05       Impact factor: 25.391

Review 7.  Adherence to antiretroviral therapy: an update of current concepts.

Authors:  Gregory M Lucas; Albert W Wu; Laura W Cheever
Journal:  Curr HIV/AIDS Rep       Date:  2004-12       Impact factor: 5.071

8.  Cost of behavioral interventions utilizing electronic drug monitoring for antiretroviral therapy adherence.

Authors:  Rafia S Rasu; David F Malewski; Julie W Banderas; Domonique Malomo Thomson; Kathy Goggin
Journal:  J Acquir Immune Defic Syndr       Date:  2013-05-01       Impact factor: 3.731

9.  Motivational interviewing and cognitive-behavioral intervention to improve HIV medication adherence among hazardous drinkers: a randomized controlled trial.

Authors:  Jeffrey T Parsons; Sarit A Golub; Elana Rosof; Catherine Holder
Journal:  J Acquir Immune Defic Syndr       Date:  2007-12-01       Impact factor: 3.731

10.  Development of a nursing intervention to facilitate optimal antiretroviral-treatment taking among people living with HIV.

Authors:  Pilar Ramirez-Garcia; José Côté
Journal:  BMC Health Serv Res       Date:  2009-07-03       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.